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Pi-Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHED), SpainSummary bacterial infection, especially spontaneous bacterial peritonitis,Hepatorenal syndrome (HRS) is a severe complication of cirrhosis
that is associated with poor survival. A rapid diagnosis of HRS and
a prompt initiation of the treatment with terlipressin and albu-
min are mandatory because this leads to an improvement of
prognosis.
This review covers the predictive value of HRS on 3-month mor-
tality beyond the MELD score and its consequential impact on the
prioritization policy to liver transplantation (LT). Moreover, it
analyzes the impact of the response to pharmacological treat-
ment on the MELD score, its possible delaying effect on the tim-
ing of LT, and suggests a way of overcoming the paradoxical effect
of terlipressin and albumin on the priority to LT in responders.
Finally, the review discusses the appropriate use of combined
liver–kidney transplantation (CLKT) in patients with HRS who
do not respond to treatment with terlipressin and albumin.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Hepatorenal syndrome (HRS) is a functional renal failure that
often occurs in patients with cirrhosis and ascites [1–3]. HRS
develops as a consequence of a severe reduction of effective cir-
culating volume due to both extreme splanchnic arterial vasodi-
latation and a reduction of cardiac output. There are two different
types of HRS. Type 1 HRS, which is often precipitated by aJournal of Hepatology 20
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combined liver–kidney transplantation.is characterized by a rapidly progressive impairment of renal
function. Despite its functional origin, the prognosis of type 1
HRS is very poor. Type 2 HRS is characterized by a stable or
slowly progressive renal failure so that its main clinical conse-
quence is not acute renal failure, but refractory ascites and its
impact on prognosis is less negative [1–3]. New types of treat-
ment such as vasoconstrictors plus albumin [4–7], transjugular
porto-systemic shunt [8], and the molecular adsorbent recirculat-
ing system [9], which were introduced in the past 10 years, are
effective in improving renal function in patients with HRS. In par-
ticular, treatment with terlipressin plus albumin, which can also
improve survival in patients with HRS, has brought about a
change in attitude towards the management of this severe com-
plication in patients with advanced cirrhosis [10–12]. The effects
on survival are strongly related to the amelioration of renal func-
tion as a result of this treatment [10,11]. Consequently, survival is
signiﬁcantly longer in responders compared with non-respond-
ers. The non-response to treatment with terlipressin and albumin
can be predicted by: (a) a high baseline value of total serum bil-
irubin [14], (b) a high baseline value of serum creatinine [15], and
(c) a low response to treatment in terms of mean arterial pressure
[14]. The ﬁnding of a predictive role for baseline serum creatinine
provides an important clinical concept in order to optimize the
results of the treatment: the early treatment of type 1 HRS with
terlipressin and albumin enhances the chances of response.
Translated into clinical practice, this means that the diagnosis
of type 1 HRS should be performed within a short time frame,
ideally 24–48 h, following the currently accepted guidelines
[13], and treatment with terlipressin and albumin should be
started as soon as the diagnosis is made [16]. Further incoming
controlled clinical trials comparing terlipressin given by intrave-
nous boluses, with terlipressin administered by continuous intra-
venous infusion, will provide additional information on another
possible way of improving the efﬁcacy of this treatment
[17]. Secondly, the combination of pharmacological therapy
with non-pharmacological therapies should be investigated,
particularly in severe cases that have a low probability of
response to pharmacological therapy alone. In this regard, a
recent study showed that the combination of terlipressin
and albumin and an extracorporeal liver support system using
fractionated plasma separation and adsorption may improve
survival in patients with type 1 HRS [18]. However, since this
observation was made with a subanalysis of a larger study,12 vol. 57 j 1135–1140
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speciﬁc studies assessing this strategy in a speciﬁc population
of patients with type 1 HRS should be performed. Meanwhile,
liver transplantation (LT) is considered the treatment of choice
for patients with cirrhosis and HRS because it ‘‘allows for both
the liver disease and associated renal failure to be cured’’. In
the perspective of LT in patients with HRS, some observations
should be made on whether to consider differently the posi-
tions of responders vs. non-responders to pharmacological
treatment of HRS.The risk of 3-month mortality in patients with HRS and the
MELD score
The MELD score incorporates three simple laboratory parameters
(serum creatinine, bilirubin, and international normalized ratio
for prothrombin time) and stratiﬁes patients according to the
severity of the disease in an objective and continuous ranking
scale. The MELD-based liver graft allocation policy has led to a
reduction in new registrations to waiting lists and mortality, to
shorter waiting times, and to an increase in transplants, without
altering overall graft and patient survival rates after transplanta-
tion. The MELD score succeeds in deﬁning the 3-month death risk
of patients with non-malignant end stage liver disease. It has
proved to be a reliable tool for prioritizing these patients in the
LT waiting list and it has contributed to optimize the allocation
of grafts according to a ‘‘sickest ﬁrst’’ policy [19]. Nevertheless,
there are conditions that are not properly considered by the
MELD score, either because they are not sufﬁciently ‘‘perceived’’
and weighted by the variables included in the score, or because
their short-term risk is progression beyond the limit of transplant
suitability, rather than death [20–22]. HRS can be included in the
ﬁrst category of such conditions. In actual fact, it has been
observed that patients with HRS have worse survival expectancy
than other populations of patients with cirrhosis with an equal
MELD score. Indeed, for any given value of MELD or MELD-Na
score, patients with HRS had shorter survival expectancy than
patients with chronic liver disease who were candidates for LT
[23]. More recently, it has been observed that not only MELD
score and serum sodium concentration, but also the presence of
hepatic encephalopathy and the phenotype of renal failure are
associated with 3-month survival [24]. Speciﬁcally, concerning
the cause of renal failure, it has been observed that patients with
hypovolemia-related renal failure, and generally patients with
HRS, have a much worse prognosis than patients with renal fail-
ure due to parenchymal nephropathy. This means that the same
abnormal value of serum creatinine may correspond to a different
clinical outcome, depending on the cause of renal impairment.
Thus, a patient with HRS should receive a priority to LT that is
not based only on the MELD score, but that also takes into
account HRS, as it is the poorest predictor of 3-month survival
among the different causes of renal failure in cirrhosis. This is
not provided by the policy of ‘‘exceptions to the MELD score’’ that
are currently used in several Western countries such as Italy [20],
France [21], and the US [22]. According to what has been recently
suggested as essential to justify any proposal for an ‘‘exception to
MELD’’, here we are dealing with a problem of mortality and not
only of quality of life. Evidence-based data can be used to sub-
stantiate our proposal, to give additional priority to patients with
HRS, making sure the subjective elements are removed or at least1136 Journal of Hepatology 2012minimized, and keeping the system of transplant allocation fair
and transparent [25].Response to terlipressin and albumin and MELD score: impli-
cations for LT
Improvement of renal function by means of terlipressin and albu-
min has been deﬁned either as a reduction of serum creatinine
below 133 lmol/L at the end of treatment (complete response)
or as a reduction in serum creatinine greater than 50% of the
pre-treatment value but with an end-of-treatment value equal
to or greater than 133 lmol/L (partial response) [10,26]. As pre-
viously reported, in patients with type 1 HRS responding to treat-
ment with terlipressin and albumin, the survival rate improved
[10,11]. Moreover, the treatment almost normalized the outcome
after LT in terms of survival, rate of renal failure, and need for
renal replacement therapy (RRT) after LT [27]. Nevertheless, with
the MELD score-based allocation system, these patients may not
get the priority to LT they need. This risk is not only related to the
limitations of MELD or MELD-Na scores in predicting the 3-
month mortality in patients with type 1 HRS, but also to the
effect of treatment on speciﬁc components of the MELD (serum
creatinine) and MELD-Na (serum creatinine and serum sodium
concentration) scores. It has been clearly shown that treatment
with terlipressin and albumin reduces the MELD score and nega-
tively affects the position of patients on the waiting list. It also
points to the fact that this problem cannot be solved by consider-
ing the MELD-Na score, since hyponatremia is also improved by
the treatment. The extreme example of this paradoxical situation
is represented by patients with continuous recurrence of type 1
HRS, which require long-term treatment with terlipressin and
albumin [28,29]. These patients probably have the highest prior-
ity to LT, but are at risk of remaining on the waiting list for
months simply because their MELD and MELD-Na scores are
reduced by the treatment. For this reason, we put forward a pro-
posal to resolve this paradoxical situation by highlighting two
different clinical scenarios: (a) the patient who responds to terli-
pressin and albumin and then maintains an adequate renal func-
tion, (b) the patient with continuous recurrence of type 1 HRS
who, therefore, requires a continuous treatment of type 1 HRS.
For reasons of clarity, we deﬁne continuous recurrence of type
1 HRS as a relapse of type 1 HRS more than once within 72 h after
treatment discontinuation [29]. Since it has been stated that
14 days is the maximum time required to treat an episode of type
1 HRS in partial responders [2], we consider the administration of
terlipressin and albumin for more than 30 days as a ‘‘long term’’
treatment, because it covers more than two subsequent episodes
of type 1 HRS. In the ﬁrst patient, we proposed to use the baseline
MELD or MELD-Na score for the deﬁnition of priority in the wait-
ing list to LT. This is basically the score calculated with the high-
est serum creatinine value and the lowest value of serum sodium
concentration just before starting treatment with terlipressin and
albumin, without taking into account the subsequent effects of
treatment on these values. It could be argued that this proposal
does not take into consideration that among the responders there
are patients with a survival longer than 6 months. However, sur-
vival at 3 months in responders was about 60%, a value which
was lower than the one predicted by their baseline MELD score
[30]. In the second patient, we propose to include treatment withvol. 57 j 1135–1140
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Fig. 1. Dynamic behavior of the ratio of urinary excretion of c-glutamyl-
transpeptidase to glomerular ﬁltration rate in patients with type 1 HRS
according to the response to pharmacological treatment. Data from Ref. [5]. B,
baseline; D, day after the initiation of treatment; the area under the dotted line
represents the normal range for this parameter in our laboratory. No response
was deﬁned by a decrease in pretreatment peak serum creatinine less than 50%.
JOURNAL OF HEPATOLOGY
terlipressin and albumin in the calculation of MELD score, as it is
already provided for RRT. This differential proposal moves from
the observation that, although to date the prognostic impact of
continuous recurrence of type 1 HRS has never been evaluated,
it is not unreasonable to speculate that it is even worse than that
related to a single episode of HRS. This is why we want to ensure
the patient with continuous recurrence of type 1 HRS, the highest
possible impact of serum creatinine on their MELD or MELD-Na
score. We think that this approach addresses and solves the prob-
lem of the priority to LT in responders to pharmacological treat-
ment of type 1 HRS, enabling us to go ahead along the road of
objectivity and transparency with respect to the policy of allocat-
ing organs, which has begun with the introduction of MELD. The
proposed exceptions to the MELD score would prevent unequal
treatment in these patients from nation to nation, between differ-
ent transplant centers in the same country and between different
patients belonging to the same center, which often occurs when
the decision-making process is entrusted to a gentleman’s agree-
ment between different transplant centers, or by a case discus-
sion within the same center. Of course, we realize that the
applicability of our proposal has some limitations. Particularly,
in relation to our ﬁrst patient, it requires a system of organ allo-
cation based on a timely update of the MELD score as it happens
in the US, Italy, and Spain. On the contrary, where the MELD
updating is mandatory on a monthly basis as in Euro Transplant,
or on a quarterly basis as in France, our proposal is likely to be
unnecessary, since these time periods assure a reasonable chance
to this patient to be transplanted on time despite creatinine
improvement. Concerning our second patient, we realized that
in some countries, patients with type 1 HRS do not receive phar-
macological treatment and are placed on RRT, therefore receiving
de facto a higher priority to LT. Nevertheless, we are conﬁdent
that the growing need of a timely update of the priorities on wait-
ing list in the sickest patients on the one hand, and the progres-
sive spread of the pharmacological therapy for HRS on the other
hand, gradually will give more meaning and relevance to our
proposal.
At this point someone may wonder: what about patients with
type 2 HRS? We realize that the severity of prognosis is not fully
expressed by the MELD score of patients with type 2 HRS either
[24]. Nevertheless, the discussion of allocation priorities to LT
for these patients according to their response to treatment with
terlipressin and albumin is a very difﬁcult task, due to the follow-
ing reasons: (a) the prognostic value of HRS is quite different in
patients with type 1 and type 2 HRS, (b) there are currently insuf-
ﬁcient data on the impact of terlipressin and albumin on clinical
outcomes in patients with type 2 HRS [24]. Nevertheless, taking
into account that a percent of patients and type 2 HRS, mainly
those with a serum creatinine >2 mg/dl [24,31], are treated with
terlipressin and albumin in clinical practice, we suggest to main-
tain the baseline MELD or MELD-Na score in the allocation of pri-
ority to LT in those who will respond to treatment. The rate of
recurrence of type 2 HRS after treatment discontinuation is high
[31]. The recurrence can meet the criteria of type 2 as well as type
1 HRS in these patients [31]. It is far from our intentions to sug-
gest that the repeated recurrence of type 2 HRS after discontinu-
ation of pharmacological treatment could imply the necessity of
giving an equal value to treatment with terlipressin and albumin
and to RRT in the calculation of MELD score. However, we think
that a further option to assure a priority to be transplanted within
3 months seems acceptable for patients with type 2 HRS in caseJournal of Hepatology 2012of continuous recurrence of type 2 HRS after the treatment
discontinuation. We propose either to consider their highest
MELD or MELD-Na score over time or to add some extra points
to their highest MELD score over time deriving them from a
speciﬁc prognostic formula for the estimation of 3-month mortal-
ity which was proposed for patients with HRS [24].Non-response to treatment with terlipressin and albumin:
implications for LT
In the perspective of LT, the main problem in non-responders to
terlipressin and albumin is not to assure them the right priority
to LT, being their baseline MELD and MELD-Na unaffected by
treatment, but rather to obtain the best result in terms of survival
and recovery of renal function after LT and to avoid futility. In
patients with type 1 HRS, a progressive increase in the urinary
excretion of biomarkers of tubular damage, among which c-glut-
amyltranspeptidase (Fig. 1), was observed in non-responders to
vasoconstrictors and albumin [5]. This preliminary observation
suggests the possibility that a progression from type 1 HRS to
acute tubular necrosis can occur in these patients. If this observa-
tion is conﬁrmed by clinical studies based on renal biopsies or
new biomarkers of renal tubular damage, it will certainly have
relevant consequences in the perspective of LT [32], since we
are potentially moving from a phenotype of ARF, which can be
completely reversed by LT alone, to a phenotype of ARF, which
cannot recover after LT alone. In only one study, comparing the
impact of LT between responders and non-responders to terli-
pressin and albumin, it has been observed that LT offered a clear
6-month survival beneﬁt to patients with HRS-1, regardless of the
therapy they received for HRS and whether or not they achieved
HRS reversal before LT [29]. In relation to the recovery of renal
function after LT, in one recent retrospective study, the HRS treat-
ment with midodrine plus octreotide and albumin was not asso-
ciated with an additional beneﬁt on glomerular ﬁltration rate
after LT [33]. Nevertheless, nowadays most of the data we can
discuss on this speciﬁc topic are related to observations made
in patients with type 1 HRS who did not receive treatment with
vasoconstrictors and albumin. These data indicate that the per-
centage of patients who will recover renal function after LT
ranges from 58% to 94% [34,35]. Several factors may contributevol. 57 j 1135–1140 1137
Table 1. UNOS recommendations for combined liver–kidney transplantation (CLKT) in 2006 [36] and 2007 [37].
UNOS recommendations in 2006 UNOS recommendations in 2007
Patients with CKD a measured CrCl [or preferentially an iothalamate 
clearance] of ≤30 ml/min
Patients with ESRD
Patients with AKI and/or HRS on dialysis for ≥6 wk. CLKT was not 
recommended in patients with AKI not requiring dialysis
Patients with CKD with GFR ≤30 ml/min
damage
Patients with AKI including HRS with creatinine ≥2 mg/dl and 
dialysis ≥8 wk
Patients with evidence of CKD and kidney biopsy demonstrating 
Patients with prolonged AKI with kidney biopsy showing fixed renal
>30% glomerulosclerosis or 30% fibrosis
CKD, chronic kidney disease; CrCl, creatinine clearance; ESRD, End Stage Renal disease; AKI, acute kidney injury; HRS, hepatorenal syndrome.
Frontiers in Liver Transplantationto the persistence of an impairment of renal function after LT,
such as intraoperative factors and postoperative factors, which
include overall calcineurin inhibitors used for immunosuppres-
sion after LT. Nevertheless, in 2006, Marik et al. showed that
HRS resolved in 16 out of 28 patients after LT, when the mean
duration of HRS prior to LT was <6 weeks [34]. In 2009, Xu
et al. showed that when the mean interval between the onset
of type 1 HRS and LT was <4 weeks, HRS resolved in 30 out of
32 patients, with eight patients dying during the ﬁrst month after
LT, and eight patients receiving post-LT RRT [35]. Although these
observations are not speciﬁcally coming from non-responders to
treatment with terlipressin and albumin, they suggest that if the
time elapsed between the onset of type 1 HRS and LT is within 4
and 6 weeks, ARF is resolved in many of the patients by LT alone,
regardless of whether or not they needed RRT in the pre-trans-
plant setting. Consequently, while we await further studies on
the new biomarkers of renal damage, the time between the onset
of type 1 HRS and LT and the severity of renal impairment are the
only criteria we can use in the decision-making process on
whether to perform LT alone or combined liver–kidney trans-
plantation (CLKT) in non-responders to terlipressin and albumin.
For these reasons, it was considered appropriate to move from
the ﬁrst two sets of recommendations for CLKT in 2006 [36]
(Table 1) and 2007 [37] respectively, to the current ones which
were introduced in 2009 [38]. In the most recent recommenda-
tions (Table 2), two criteria can be considered as being tailored
to patients with type 1 HRS who are non-responders to terlipres-
sin and albumin: (a) sustained ARF requiring dialysis for 6 weeks
or more (deﬁned as dialysis at least twice a week for 6 consecu-
tive weeks) or (b) sustained ARF not requiring dialysis with a GFR
625 ml/min for 6 weeks or more measured at least once a week
by MDRD6 formula or directly by means of inulin or other mark-
ers [36]. Based on the current limited knowledge on the evolution
of type 1 HRS in non-responders to terlipressin and albumin, this
seems to be a good balance between the need to avoid the devel-
opment of CKD after LT in these patients on the one hand, and,
the requests for CLKT, which have been already expanded in
the MELD era, on the other hand.Conclusions
HRS is an extremely severe complication of cirrhosis, with a deep
negative impact on prognosis in patients who are not treated
with terlipressin and albumin, or in patients who do not respond
to this pharmacological therapy. A prompt diagnosis and treat-1138 Journal of Hepatology 2012ment may improve LT rates and post-LT outcomes in transplant
candidates with type 1 HRS. Nevertheless, in order to optimize
the results of pharmacological treatment, responders should
receive the right priority in the waiting list, taking into account
not only the speciﬁc value of HRS per se on 3-month mortality
beyond the MELD score, but also considering that the effect of
terlipressin and albumin in lowering serum creatinine can reduce
the baseline MELD score in these patients and therefore delay the
timing of LT. The paradoxical effect of treatment in patients with
type 1 HRS who respond to terlipressin and albumin can be
avoided either by continuing to consider the baseline MELD, or
by considering the pharmacological treatment of HRS as dialysis,
in the calculation of the MELD score (key points).
Key Points 
• In order to optimize the results of the pharmacological
treatment of HRS, responders should receive the right
priority in the waiting list, taking into account not only the
 value of HRS per se on three-month mortality
beyond the MELD score, but also considering that the
pharmacological treatment of HRS can reduce the
baseline MELD score in these patients 
• The paradoxical effect of treatment in patients with type
1 HRS who respond to terlipressin and albumin can be
avoided either by continuing to consider the baseline
MELD, or, in case of continuous recurrence of HRS by
considering the pharmacological treatment of HRS as
dialysis in the calculation of the MELD score
• The baseline MELD should be maintained also in 
patients with severe type 2 HRS who responded to
the pharmacological treatment. A further option to 
assure a priority should be given to patients with type 2
HRS in case of repeated recurrences of HRS after the
discontinuation of the treatment, taking into account their
highest MELD-Na score over time
• The applicability of these proposals has some limitations,
particularly in relation to the variability of the allocation
systems worldwide
specific
With regard to non-responders to the pharmacological treat-
ment, some data show a possible evolution of ARF from the
HRS phenotype to an ATN phenotype with a consequential loss
of the potential reversibility of ARF after LT alone. While waitingvol. 57 j 1135–1140
Table 2. Current UNOS recommendations for combined liver–kidney transplantation (CLKT) [38].
a) CKD requiring dialysis 
b) CKD not requiring dialysis: documentation of both GFR ≤30 ml/min [by MDRD6 or iothalamate measurement] and proteinuria [>3 g 
protein per day with 24 h protein measurement or urine protein/creatinine ratio >3] is required
weeks] is required
d) Sustained AKI not requiring dialysis: documentation of a GFR ≤25 ml/min for 6 wk or more by MDRD6 or direct measurement [iothala-
mate or iohexol] is required at least once a week
e) Sustained AKI: patients may also qualify for CLKT listing with a combination of time in categories (c) and (d) above for a total of 6 wk
f) Metabolic disease 
c) Sustained AKI requiring dialysis: documentation of dialysis for 6 wk or more [defined as dialysis at least twice a week for 6 consecutive
CKD, chronic kidney disease; GFR, glomerular ﬁltration rate; MDRD6, modiﬁcation of diet in renal disease formula 6; AKI, acute kidney injury.
JOURNAL OF HEPATOLOGYfor further conﬁrmation of these data, the current indications to
CKLD elaborated by the International transplant community
seem to represent a good balance in order to avoid development
of CKD after LT in these patients, without further increasing the
requirements for CLKT.Conﬂict of interest
The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.
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